$135 Million is the total value of Omega Fund Management, LLC's 14 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| REPL | Replimune | $51,035,000 | -37.9% | 5,103,455 | 0.0% | 37.84% | -2.7% | |
| TBIO | Buy | Translate Bio | $18,282,000 | -25.0% | 2,437,603 | +0.0% | 13.56% | +17.5% |
| KZR | Sell | KezarLife Sciences | $15,945,000 | +7.4% | 675,623 | -2.5% | 11.82% | +68.4% |
| PRTK | Paratek Pharmaceuticals | $13,340,000 | -47.1% | 2,600,410 | 0.0% | 9.89% | -17.1% | |
| OBSV | ObsEva | $12,652,000 | -29.8% | 999,364 | 0.0% | 9.38% | +10.1% | |
| FGEN | FibroGen | $6,046,000 | -23.8% | 130,646 | 0.0% | 4.48% | +19.4% | |
| CBAY | CymaBay Therapeutics | $4,340,000 | -29.0% | 551,477 | 0.0% | 3.22% | +11.3% | |
| CDTX | Cidara Therapeutics | $3,546,000 | -46.6% | 1,508,794 | 0.0% | 2.63% | -16.3% | |
| EPIX | BSSA Pharma | $2,278,000 | -30.0% | 1,084,848 | 0.0% | 1.69% | +9.7% | |
| PIRS | Pieris Pharmaceuticals | $2,070,000 | -52.5% | 778,230 | 0.0% | 1.54% | -25.6% | |
| DRNA | Sell | Dicerna Pharmaceuticals | $1,787,000 | -47.6% | 167,157 | -25.2% | 1.32% | -17.9% |
| JNCE | Jounce Therapeutics | $1,786,000 | -48.2% | 529,965 | 0.0% | 1.32% | -18.8% | |
| SNNAQ | Sienna Biopharmaceuticals | $1,760,000 | -84.3% | 758,610 | 0.0% | 1.30% | -75.5% | |
| EGLTQ | Egalet | $7,000 | -98.1% | 2,889,926 | 0.0% | 0.01% | -97.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-11
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Paratek Pharmaceuticals, Inc. | 34 | Q1 2023 | 39.1% |
| FibroGen, Inc. | 28 | Q3 2021 | 14.3% |
| Jounce Therapeutics | 25 | Q1 2023 | 11.6% |
| Pieris Pharmaceuticals | 23 | Q1 2021 | 5.2% |
| Replimune Group | 21 | Q3 2023 | 47.2% |
| Cidara Therapeutics | 20 | Q3 2021 | 5.8% |
| Morphic Holding | 18 | Q3 2023 | 22.0% |
| Immunic Inc | 18 | Q3 2023 | 9.0% |
| Dicerna Pharmaceuticals | 18 | Q1 2019 | 3.7% |
| Egalet | 17 | Q4 2018 | 19.6% |
View Omega Fund Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| 13F-HR/A | 2021-11-15 |
View Omega Fund Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.